The Drug Controller General of India (DCGI) has approved Wockhardt’s two new antibiotics, EMROK (IV) and EMROK O (oral), for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteraemia.
The approval is based on phase three study involving 500 patients in 40 centres across India.
The drugs will target super bugs such as Methicillin-resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR) among patients The size of Indian antibiotic market is estimated at ₹16,000 crore, growing at 7%.
Workhardt, which will launch these drugs in India shortly, plans ...
Read the full text thehindu